Lecap Asset Management Ltd. Takes Position in Halozyme Therapeutics, Inc. $HALO

Lecap Asset Management Ltd. purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 7,963 shares of the biopharmaceutical company’s stock, valued at approximately $584,000.

Other large investors have also bought and sold shares of the company. HB Wealth Management LLC acquired a new position in shares of Halozyme Therapeutics in the third quarter worth approximately $232,000. Spire Wealth Management raised its position in shares of Halozyme Therapeutics by 3,390.1% in the 3rd quarter. Spire Wealth Management now owns 4,956 shares of the biopharmaceutical company’s stock worth $363,000 after acquiring an additional 4,814 shares in the last quarter. Moran Wealth Management LLC boosted its position in shares of Halozyme Therapeutics by 261.9% during the 3rd quarter. Moran Wealth Management LLC now owns 35,445 shares of the biopharmaceutical company’s stock valued at $2,600,000 after purchasing an additional 25,652 shares in the last quarter. KLP Kapitalforvaltning AS increased its holdings in Halozyme Therapeutics by 1.2% in the third quarter. KLP Kapitalforvaltning AS now owns 25,700 shares of the biopharmaceutical company’s stock worth $1,885,000 after purchasing an additional 300 shares in the last quarter. Finally, CoreCap Advisors LLC acquired a new stake in shares of Halozyme Therapeutics during the 3rd quarter worth approximately $429,000. 97.79% of the stock is owned by institutional investors.

Insider Activity

In other news, COO Cortney Caudill sold 4,263 shares of Halozyme Therapeutics stock in a transaction on Saturday, November 1st. The shares were sold at an average price of $65.19, for a total transaction of $277,904.97. Following the completion of the sale, the chief operating officer directly owned 12,737 shares of the company’s stock, valued at approximately $830,325.03. The trade was a 25.08% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Bernadette Connaughton sold 2,000 shares of Halozyme Therapeutics stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $70.25, for a total value of $140,500.00. Following the sale, the director directly owned 40,123 shares of the company’s stock, valued at approximately $2,818,640.75. This trade represents a 4.75% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 45,661 shares of company stock worth $3,139,257 in the last three months. Corporate insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Trading Down 4.0%

Shares of HALO opened at $72.13 on Friday. The firm has a market cap of $8.48 billion, a P/E ratio of 15.19, a price-to-earnings-growth ratio of 0.33 and a beta of 0.94. Halozyme Therapeutics, Inc. has a fifty-two week low of $47.50 and a fifty-two week high of $79.50. The company has a debt-to-equity ratio of 1.59, a quick ratio of 1.37 and a current ratio of 1.59. The business has a 50-day moving average of $68.13 and a 200 day moving average of $66.46.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share for the quarter, beating analysts’ consensus estimates of $1.63 by $0.09. The business had revenue of $354.26 million during the quarter, compared to analyst estimates of $339.18 million. Halozyme Therapeutics had a net margin of 47.91% and a return on equity of 156.95%. Halozyme Therapeutics’s revenue was up 22.1% compared to the same quarter last year. During the same period in the previous year, the business earned $1.27 EPS. As a group, research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Analysts Set New Price Targets

Several analysts have recently commented on the company. Morgan Stanley reduced their target price on Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating for the company in a research note on Monday, October 20th. TD Cowen boosted their target price on shares of Halozyme Therapeutics from $79.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday. Benchmark increased their price objective on Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a research note on Wednesday, September 24th. The Goldman Sachs Group reissued a “sell” rating and issued a $56.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, December 4th. Finally, Weiss Ratings raised shares of Halozyme Therapeutics from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Monday, December 29th. Eight analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $76.45.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.